Get the Stockscreener App
25.31
1.57%
0.39
After Hours:
25.55
0.24
+0.95%
Arcutis Biotherapeutics Inc stock is traded at $25.31, with a volume of 2.30M.
It is up +1.57% in the last 24 hours and up +34.27% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$24.92
Open:
$24.69
24h Volume:
2.30M
Relative Volume:
1.13
Market Cap:
$3.03B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-6.4566
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
+25.86%
1M Performance:
+34.27%
6M Performance:
+69.75%
1Y Performance:
+204.57%
1-Day Range:
$24.63
$25.56
1-Week Range:
$19.60
$27.08
52-Week Range:
$8.29
$27.08
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
25.31 | 3.05B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Advanced analytics toolkit walkthrough for Arcutis Biotherapeutics Inc.2025 Short Interest & Accurate Buy Signal Notifications - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investorsShort Setup & Fast Gain Stock Trading Tips - newser.com
Is Arcutis Biotherapeutics Inc. a candidate for recovery playEarnings Performance Report & AI Powered Market Entry Strategies - newser.com
Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.2025 Price Targets & Precise Trade Entry Recommendations - newser.com
Arcutis Biotherapeutics Achieves 186.45% Return, Establishing It as a Multibagger in Biotechnology - Markets Mojo
Multi asset correlation models including Arcutis Biotherapeutics Inc.July 2025 Review & Capital Efficiency Focused Strategies - newser.com
Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averagesWeekly Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableIPO Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Leading vs lagging indicators on Arcutis Biotherapeutics Inc. performancePortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Will Arcutis Biotherapeutics Inc. stock deliver consistent dividendsJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to global recession fearsTrend Reversal & Weekly Setup with High ROI Potential - newser.com
HC Wainwright Has Positive Forecast for ARQT FY2025 Earnings - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Institutional & Verified Swing Trading Watchlist - newser.com
What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.July 2025 PreEarnings & Growth Focused Entry Point Reports - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 40,000 Shares - MarketBeat
Why Arcutis Biotherapeutics (ARQT) Is Up 23.9% After Expanding ZORYVE to Pediatric Atopic Dermatitis - Yahoo Finance
HC Wainwright Has Positive Outlook for ARQT Q4 Earnings - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
What the charts say about Arcutis Biotherapeutics Inc. todayChart Signals & Reliable Price Action Trade Plans - newser.com
How high can Arcutis Biotherapeutics Inc. stock go2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growthJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - newser.com
Volatility clustering patterns for Arcutis Biotherapeutics Inc.Trade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Arcutis Biotherapeutics CEO Watanabe sells $1m in shares By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics CEO Watanabe sells $1m in shares - Investing.com India
Goldman Sachs Maintains Arcutis Biotherapeutics (ARQT) Neutral Recommendation - Nasdaq
Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis - Dermatology Times
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock - Yahoo Finance
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments - The Manila Times
Tori Spelling Joins Arcutis Biotherapeutics in Launching Free to Be Me Campaign to Raise Awareness About Eczema and Seborrheic Dermatitis - Quiver Quantitative
Arcutis (NASDAQ: ARQT) joins Tori Spelling in 'Free to Be Me' for 36M patients - Stock Titan
Arcutis Biotherapeutics (ARQT) Launches ZORYVE Cream for Young C - GuruFocus
Arcutis Biotherapeutics launches new topical cream for children's eczema - Traders Union
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - MarketScreener
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 (2025-10-30) - Seeking Alpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Arcutis Biotherapeutics (ARQT) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Arcutis Biotherapeutics, Inc. $ARQT Stake Lowered by Jennison Associates LLC - MarketBeat
Why hedge funds are buying Arcutis Biotherapeutics Inc. stockJuly 2025 Market Mood & High Return Trade Guides - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressures2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):